Target Name: KCP
NCBI ID: G375616
Review Report on KCP Target / Biomarker Content of Review Report on KCP Target / Biomarker
KCP
Other Name(s): KCP_HUMAN | KCP variant 1 | Kielin/chordin-like protein 1 | KCP1 | kielin | CRIM-2 | cysteine-rich motor neuron 2 protein | cysteine-rich BMP regulator 2 | kielin/chordin-like protein | Kielin/chordin-like protein | cysteine rich BMP regulator 2 (chordin-like) | NET67 | KCP-1 | Kielin/chordin-like protein, transcript variant 1 | Cysteine-rich motor neuron 2 protein | CRIM2 | Cysteine-rich BMP regulator 2 | Kielin/chordin-like protein precursor (isoform 1) | kielin cysteine rich BMP regulator | kielin/chordin-like protein 1

KCP: A GPCR7 Receptor for Neurotransmitter Signaling and Cellular Signaling

KCP (KCP_HUMAN), also known as G protein-coupled receptor 7 (GPCR7), is a protein that plays a crucial role in cellular signaling. It is a member of the G protein-coupled receptor family, which is a large family of transmembrane proteins that play a key role in cellular signaling. GPCR7 is widely expressed in various tissues and cells, including neurons, heart cells, and blood vessels. Its function is not well understood yet, but it is thought to play a role in cell signaling, specifically in the regulation of neurotransmitter signaling.

KCP is a protein that consists of 158 amino acid residues. It has an extracellular domain that is similar to other GPCR proteins, with a catalytic active center and a zinc ion binding site. The extracellular domain is responsible for the protein's ability to interact with zinc ions, which are important for its function.

One of the unique features of KCP is its unique ability to interact with the neurotransmitter serotonin. Serotonin is a well-known neurotransmitter that plays a critical role in the regulation of mood, appetite, and sleep. It is thought to be involved in the development and maintenance of certain behaviors, such as anxiety and depression.

KCP has been shown to play a role in the regulation of serotonin signaling in the brain. Studies have shown that KCP is expressed in the brain and that it is involved in the regulation of serotonin receptor function. Additionally, altered levels of KCP have been observed in individuals with mental health conditions, such as depression and anxiety.

KCP is also involved in the regulation of other signaling pathways, including the regulation of pain and inflammation. It is thought to play a role in the regulation of pain perception and the modulation of pain responses. Additionally, KCP is involved in the regulation of inflammation , which is important for the development of various diseases.

Despite its involvement in various signaling pathways, the function of KCP is not well understood. It is not known what the protein does in the cell or what its downstream targets are. Additionally, the mechanisms behind KCP's function are not well understood, and further research is needed to fully understand its role in cellular signaling.

In conclusion, KCP is a protein that is widely expressed in various tissues and cells that plays a crucial role in cellular signaling. Its function is not well understood, but it is thought to play a role in the regulation of serotonin signaling, pain and inflammation . Further research is needed to fully understand its role in cellular signaling and its potential as a drug target.

Protein Name: Kielin Cysteine Rich BMP Regulator

Functions: Enhances bone morphogenetic protein (BMP) signaling in a paracrine manner. In contrast, it inhibits both the activin-A and TGFB1-mediated signaling pathways (By similarity)

The "KCP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

KCTD1 | KCTD10 | KCTD11 | KCTD12 | KCTD13 | KCTD13-DT | KCTD14 | KCTD15 | KCTD16 | KCTD17 | KCTD18 | KCTD19 | KCTD2 | KCTD20 | KCTD21 | KCTD21-AS1 | KCTD3 | KCTD4 | KCTD5 | KCTD5P1 | KCTD6 | KCTD7 | KCTD8 | KCTD9 | KDELR1 | KDELR2 | KDELR3 | KDF1 | KDM1A | KDM1B | KDM2A | KDM2B | KDM3A | KDM3B | KDM4A | KDM4B | KDM4C | KDM4D | KDM4E | KDM5A | KDM5A-GATAD1-EMSY chromatin complex | KDM5B | KDM5C | KDM5D | KDM6A | KDM6B | KDM7A | KDM7A-DT | KDM8 | KDR | KDSR | KEAP1 | Kelch-like protein | KERA | Keratin | KHDC1 | KHDC1L | KHDC1P1 | KHDC3L | KHDC4 | KHDRBS1 | KHDRBS2 | KHDRBS3 | KHK | KHNYN | KHSRP | KHSRPP1 | KIAA0040 | KIAA0087 | KIAA0232 | KIAA0319 | KIAA0319L | KIAA0408 | KIAA0513 | KIAA0586 | KIAA0753 | KIAA0754 | KIAA0825 | KIAA0930 | KIAA1107 | KIAA1143 | KIAA1191 | KIAA1210 | KIAA1217 | KIAA1328 | KIAA1522 | KIAA1549 | KIAA1549L | KIAA1586 | KIAA1614 | KIAA1656 | KIAA1671 | KIAA1671-AS1 | KIAA1755 | KIAA1958 | KIAA2012 | KIAA2013 | KIAA2026 | KICS2 | KIDINS220